Introduction
============

The myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic stem cell (HSC) malignancies characterized by blood cell dysplasia and peripheral blood cytopenia. Approximately 30--40% of MDS patients will develop acute myeloid leukemia (AML).^[@bib1]^

The recent discovery of somatic splicesomal mutations in MDS has revealed a new leukemogenic pathway involving spliceosomal dysfunction.^[@bib2],\ [@bib3]^ Somatic mutations in the splicing factor genes *SF3B1*, *U2AF1*, *SRSF2* and *ZRSR2* are frequent in MDS patients.^[@bib4]^ Importantly, these genes encode proteins that are all involved in 3′-splice site recognition during pre-messenger RNA (pre-mRNA) processing. Splicing factor gene mutations occur in over 50% of MDS patients, are highly specific to this disorder, and occur in a mutually exclusive manner.^[@bib5],\ [@bib6],\ [@bib7]^

*SF3B1*, encoding a core component of the U2 small nuclear ribonucleoprotein, involved in the recognition of the branchpoint sequence, is the most commonly mutated gene found in MDS (20--28% of all patients).^[@bib2],\ [@bib8],\ [@bib9]^ We and others have shown that mutations of the splicing factor *SF3B1* are found in a high percentage (\>70%) of MDS patients whose disease is characterised by the presence of ring sideroblasts, including both refractory anemia with ring sideroblasts (RARS) and refractory cytopenia with multilineage dysplasia and ring sideroblasts (RCMD-RS).^[@bib2],\ [@bib8]^ The close association between *SF3B1* mutation and the presence of ring sideroblasts is consistent with a causal relationship and makes this the first gene to be strongly associated with a specific morphological feature of MDS. Ring sideroblasts are characterised by an excess accumulation of iron in the mitochondria of erythroblasts,^[@bib10]^ and *SF3B1* mutant RARS cases show altered iron distribution characterised by coarse iron deposits compared with wild-type RARS cases.^[@bib11]^ *SF3B1* mutations are generally more prevalent in low-risk MDS and have been shown to be independent predictors of favorable clinical outcome in MDS in most studies.^[@bib8],\ [@bib11]^ The clinical consequences of *SF3B1* mutation in MDS are clear, but the functional consequences of these mutations in human cells remain poorly understood. Altered RNA splicing has been suggested as the mechanism underlying the observed phenotypic changes concomitant to splicing factor gene mutations, including *SF3B1*; ^[@bib3],\ [@bib12],\ [@bib13]^ however, the target genes in the HSC of MDS cases with *SF3B1* mutations are yet to be defined.

*SF3B1* mutations in MDS are primarily heterozygous point mutations. The presence of hotspots and the absence of nonsense or frameshift mutations in *SF3B1* in MDS patients suggest that *SF3B1* mutations are likely to be gain/change-of-function (neomorphic) mutations. A heterozygous *Sf3b1*^+/−^ knockout mouse model has been shown to develop ring sideroblasts, suggesting that haploinsufficiency of *SF3B1* may lead to their formation.^[@bib11]^ Recent similar studies have not made this observation, however.^[@bib14],\ [@bib15]^ Thus, it is yet to be determined whether *SF3B1* mutations found in MDS are loss-of-function mutations or gain/change-of-function mutations. In this study, we thus evaluated the effects of *SF3B1* knockdown on cell growth, gene expression and splicing in a range of myeloid cell lines and performed RNA sequencing (RNA-Seq) on the CD34^+^ cells of MDS patients harboring *SF3B1* mutations.

Materials and methods
=====================

Myeloid cell lines culture
--------------------------

K562, HEL, TF1 and SKM1 cells were cultured in Roswell Park Memorial Institute medium 1640 (Sigma-Aldrich, Gillingham, UK) containing 10% fetal bovine serum, at 37 °C and 5% CO~2~. TF1 and SKM1 cultures were supplemented with 2 and 1 ng/ml of granulocyte-macrophage colony-stimulating factor, respectively.

*SF3B1* knockdown
-----------------

Three non-overlapping small interfering RNAs (siRNAs) targeting *SF3B1* and two different scramble sequences with guanine--cytosine content similar to the siRNA sequences (Stealth Select RNAi, Invitrogen) were used to knock down *SF3B1* in myeloid cell lines. For each transfection, 30 pmol of siRNA and 2 × 10^6^ cells were electroporated in an Amaxa Nucleofector I, using the Amaxa cell optimization kit V (Amaxa, Gaithersburg, MD, USA). Evaluation of green fluorescent protein-positive cells obtained using the pmaxGFP fluorescent expression plasmid confirmed \>80% of successfully transfected cells after 24 h. Readout data are reported as mean±s.e.m. Statistical analysis was performed using Student\'s *t*-test.

Cell growth assay
-----------------

Live and dead cells were assessed by trypan blue viability testing and counted using a hemocytometer.

Cell cycle analysis
-------------------

Cells were fixed with ice cold methanol, incubated with 40 μg/ml propidium iodide and 10 μg/ml RNaseA, as previously described.^[@bib16]^ Data were acquired on a BD LSRII flow cytometer (BD Bioscience; Franklin Lakes, NJ, USA) and analyzed using FLOWJO software 7.6.4 (FlowJo, Ashland, OR, USA).

Erythroid differentiation
-------------------------

To induce erythroid differentiation, K562, TF1 and HEL cells were cultured with hemin 50 μ[m]{.smallcaps} for 72 h. Erythroid differentiation was studied by analyzing the expression level of γ*-globin* (*HBG1*) using quantitative real-time PCR (qRT-PCR) as described previously.^[@bib17]^ Expression of the erythroid markers CD36, CD71 and CD235a was evaluated by flow cytometry as described previously.^[@bib16]^

Quantitative real-time PCR
--------------------------

Total RNA was reverse transcribed using Retroscript kit (Ambion, Life Technologies, Paisley, UK). The expression levels of *SF3B1*, *ABCB7*, *FTMT*, *HBG1, KLF1* and *B2M* were determined using Assays-on-Demand (Applied Biosystems, Foster City, CA, USA). *B2M* expression levels were used to normalize for differences in input complementary DNA (cDNA). Triplicate samples were run on a LightCycler 480 Real-time PCR system (Roche Diagnostics, Lewes, UK) and expression ratios were calculated using the ddCT method.^[@bib18]^

Gene expression profiling
-------------------------

Total RNA (100 ng for each sample) was amplified and labeled with the 3′ IVT Express Kit (Affymetrix, Santa Clara, CA, USA), and hybridized to Affymetrix Human Genome U133 Plus 2.0 GeneChips, as described previously.^[@bib19],\ [@bib20]^ CEL files were pre-processed using Robust Multi-chip Average and data analysis was performed using GeneSpring 7.3.1 (Agilent, Santa Clara, CA, USA). Pathway analysis was performed using Ingenuity Pathway Analysis (IPA) 7.5 (Qiagen, Manchester, UK), as previously described.^[@bib19]^ Analysis of gene set up- or downregulation was performed using Gene Set Enrichment Analysis,^[@bib21]^ as previously described (false discovery rate\<0.1).^[@bib2]^

Splicing analysis using human genome exon-junction microarray
-------------------------------------------------------------

Total RNA was DNAse treated (Invitrogen), purified (Agencourt RNA Clean XP) and amplified (100 ng) using Ambion WT Expression Kit (Affymetrix). The cDNA was subsequently fragmented and labeled using WT terminal labeling kit (Affymetrix). Samples were hybridized onto Affymetrix Human genome exon-junction arrays, which on average contain 119 unique probes per gene spanning every exon and known exon--exon junction. CEL files were analyzed using GenoSplice technology ([www.genosplice.com](http://www.genosplice.com)).^[@bib22],\ [@bib23]^ Data were normalized using quantile normalization. Analysis at the exon level was performed taking into account only exon probes. Analysis at the splicing variant level was performed by taking into account exon--exon junction probes using the FAST DB splicing patterns annotation (release fastdb_2012_2). Unpaired Student\'s *t*-test was used to determine exon and splicing pattern variation between cells with *SF3B1* knockdown and scramble controls. Genes were considered significantly deregulated when fold change was ⩾1.5 and *P*-value \<0.05. Gene Ontology, KEGG and REACTOME analyses of differentially regulated genes were performed using DAVID.^[@bib24]^

Splicing analysis using qRT-PCR and Sanger sequencing
-----------------------------------------------------

Splicing analysis of *TP53* was performed using Sanger sequencing of gel-extracted individual bands from PCR-amplified cDNA. Primers and PCR conditions are listed in [Supplementary Table S1](#sup1){ref-type="supplementary-material"}.

Splicing analysis of cyclins *CCNA2* and *STK6* was performed using a qRT-PCR on cDNA, using primers specific for splice junctions corresponding to exon inclusion or skipping.^[@bib25]^ Primers are listed in [Supplementary Table S2](#sup1){ref-type="supplementary-material"}. *TBP* expression levels were used to normalize for differences in input cDNA.

RNA sequencing
--------------

Bone marrow samples were obtained from MDS patients and healthy controls and CD34^+^ cells isolated using MACS magnetic cell separation columns (Miltenyi Biotec, Germany), as described previously.^[@bib19],\ [@bib20]^ RNA extracted from bone marrow CD34^+^ cells obtained from 12 MDS patients and 5 healthy controls was used for deep RNA-Seq. Eight of the 12 MDS cases (four RARS and four RCMD-RS) had *SF3B1* gene mutation, whereas four cases (all RCMD) had no known mutations in splicing factor genes (*SF3B1, SRSF2, U2AF1* or *ZRSR2)* ([Supplementary Table S3](#sup1){ref-type="supplementary-material"}), as determined by targeted next-generation sequencing data from a previous study.^[@bib7]^

Total RNA was DNase treated (Invitrogen), purified using XP beads (Beckman Coulter, High Wycombe, UK) and processed (100 ng) using NEBNext Ultra directional mRNA Library prep (NEB, Hitchin, UK) as per the manufacturer\'s protocol for Illumina with two alterations: custom indexes were designed in house and an additional purification step was performed using XP beads (Beckman Coulter) rather than size selection. Samples were run on HiSeq2000 Illumina sequencing machine (Illumina, San Diego, CA, USA). Sequencing reads were mapped to the human genome using TopHat,^[@bib26]^ which can handle reads spanning exon--exon boundaries. Data analysis was performed using edgeR^[@bib27]^ to evaluate the whole transcript expression (false discovery rate\<0.05) and with DEXSeq^[@bib28]^ to evaluate differential exon usage (false discovery rate\<0.05). At the expression level, only genes with at least 10 reads in four or more samples were included in the analysis; at the exon level, exons with fewer than 10 reads were excluded. Gender was included as an additional factor in the DEXSeq model testing for differential exon usage. Selected differentially expressed exons were validated using qRT-PCR ([Supplemetary Figure S1](#sup1){ref-type="supplementary-material"}, [Supplementary Information](#sup1){ref-type="supplementary-material"}). Integrative Genomics Viewer (IGV) v2.3 (<http://www.broadinstitute.org/igv/>) was used for visualization of the sequence reads. Pathway analysis was performed using IPA and Gene Set Enrichment Analysis, as described above. The data discussed in this publication have been deposited in NCBI\'s Gene Expression Omnibus and are accessible through GEO Series accession number GSE63569.

Results
=======

*SF3B1* knockdown inhibits cell growth, induces cell cycle arrest and impairs erythroid differentiation
-------------------------------------------------------------------------------------------------------

*SF3B1* was knocked down using siRNA technology in four myeloid cell lines (TF1, K562, HEL and SKM1) that we found to be wild type for *SF3B1* ([Supplementary Information](#sup1){ref-type="supplementary-material"}), resulting in a significant decrease in expression ranging between 50 and 60% ([Figure 1a](#fig1){ref-type="fig"}).

Cell growth was inhibited in all four cell lines with *SF3B1* knockdown in comparison with the scramble control ([Figure 1b](#fig1){ref-type="fig"}). Cell cycle arrest in different phases was detected in different myeloid cell lines with *SF3B1* knockdown ([Figure 1c](#fig1){ref-type="fig"}). K562 cells showed a significant G2M cell cycle arrest with a concomitant reduction in the percentage of cells in the G1 and S phase. TF1 cells showed a significant decrease in the percentage of cells in the S phase. HEL cells showed a significant decrease in the percentage of cells in the G1 phase and a significant increase in the sub-G1 cell population, indicating increased apoptosis. Similarly, SKM1 cells showed a significant decrease in the percentage of cells in S and G2M phase with a concomitant increase in the percentage of cells in the sub-G1 and G1 phase, indicating cell cycle arrest in the G1 phase and an increase in apoptosis ([Figure 1c](#fig1){ref-type="fig"}).

Three cell lines (TF1, K562 and HEL) with *SF3B1* knockdown were cultured with hemin to induce erythroid differentiation. We assessed the expression of the erythroid differentiation markers *HBG1* and *KLF1* using qRT-PCR. A significant reduction in the expression of *HBG1* and *KLF1* was observed in TF1 and K562 cell lines with *SF3B1* knockdown ([Figure 1d](#fig1){ref-type="fig"}). In addition, we observed a reduction in the percentage of CD36+CD71+ and CD71+CD235a+ erythroid populations (significant for the CD36+CD71+ population) in K562 cells with *SF3B1* knockdown compared with the scramble control ([Figure 1e](#fig1){ref-type="fig"}), suggesting that normal *SF3B1* function is required for erythroid differentiation.^[@bib17]^

RARS is characterized by *FTMT* accumulation and low expression levels of the iron transporter *ABCB7*.^[@bib17],\ [@bib29]^ We have previously shown that *SF3B1* knockdown leads to decreased *ABCB7* expression and increased *FTMT* expression in K562 cells.^[@bib17]^ In this study, we have extended these observations to the other three myeloid cell lines investigated ([Figure 2a](#fig2){ref-type="fig"}). In addition, restoration of *SF3B1* expression to normal levels after 10 days of culture was followed by restoration of *ABCB7* expression levels to normal ([Supplementary Figure S2](#sup1){ref-type="supplementary-material"}).

Taken together, these data show that *SF3B1* knockdown results in inhibition of cell growth, induction of cell cycle arrest and impairment of erythroid differentiation in myeloid cell lines.

*SF3B1* knockdown alters gene expression
----------------------------------------

To evaluate the effects of *SF3B1* knockdown on global gene expression, gene expression profiling was performed in the four myeloid cell lines. For each cell line, we compared the expression profiles of cells treated with two different siRNAs targeting *SF3B1* with those of cells treated with a scramble control, 48 h post transfection.

We identified many genes that were up- or downregulated by \>2-fold in each cell line treated with *SF3B1* siRNAs ([Supplementary Figure S3A and S3B](#sup1){ref-type="supplementary-material"}). Four genes were upregulated (*TFDP1, LOC100505759, MKRN1* and *WRNIP1*) and five genes were downregulated (*ZC3H7A, CREBZF, SGK494, WSB1* and two probesets for *SF3B1*) in all four cell lines with *SF3B1* knockdown.

Pathway analysis was performed on the up- and downregulated genes in each cell line with *SF3B1* knockdown using IPA. Significant deregulation of pathways related to cell cycle regulation was observed in all cell lines and of mTOR signaling and AMPK signaling pathways in three cell lines ([Table 1](#tbl1){ref-type="table"}). We performed Gene Set Enrichment Analysis to identify pathways and processes showing coordinated up- or downregulation. Upregulated gene sets include p53 signaling in K562 and SKM1 cells, and several gene sets associated with regulation of transcription, spliceosome and splicing in K562 cells ([Supplementary Table S4](#sup1){ref-type="supplementary-material"}). Downregulated gene sets associated with the mitochondrial function were found in K562 and TF1 cells, and with cell cycle regulation in SKM1 and HEL cells ([Supplementary Table S4](#sup1){ref-type="supplementary-material"}). These data show that *SF3B1* knockdown in the cell lines studied results in deregulation of many genes and pathways including cell cycle and RNA processing.

*SF3B1* knockdown impact on splicing
------------------------------------

The genome-wide effects of *SF3B1* knockdown on splicing were investigated in two myeloid cell lines (K562 and TF1) using human genome exon-junction arrays. The splicing profile of cells with *SF3B1* knockdown (using two different siRNA per cell line) was compared with that of cells transfected with the scramble control.

We observed 2027 differentially expressed exons from 1419 genes, and 507 significant differentially regulated splicing variants (including exon skipping, intron retention and alternative splice sites) of 384 genes in cells with *SF3B1* knockdown. For example, we observed differential exon usage of *CDC7* and *SRSF11* in the data from both the cell lines, and of *TP53* in TF1 cells. We found a significant overrepresentation of 3′ acceptor splice sites affected by alternative splicing events compared with 5′ donor splice sites (5:1 ratio, *P*=0.0027, *χ*^2^ test with Yates\' correction), consistent with the known role of SF3B1 in the recognition of 3′ splice sites. Gene ontology analysis was performed using DAVID (<http://david.abcc.ncifcrf.gov/>), and many themes showed significant enrichment of genes affected at the level of exon usage and splice variants ([Table 2](#tbl2){ref-type="table"}). Cell cycle and RNA degradation were found to be consistently deregulated at both levels ([Table 2](#tbl2){ref-type="table"}). We investigated *TP53* differential exon usage by PCR amplification and Sanger sequencing of gel-extracted bands. We observed exon skipping that was present in the *SF3B1* knockdown cells only ([Figure 2b](#fig2){ref-type="fig"}).

We also investigated whether two cell cycle genes (*CCNA2* and *STK6*) previously shown to be aberrantly spliced in HeLa cells with *SF3B1* knockdown,^[@bib25]^ were also aberrantly spliced in K562 cells with *SF3B1* knockdown in our study. Consistent with the finding in HeLa cells, we observed aberrant splicing of these genes using a qRT-PCR strategy as described previously ([Figure 2c and d](#fig2){ref-type="fig"}).^[@bib25]^

RNA-Seq in HSPC from MDS patients with *SF3B1* mutations
--------------------------------------------------------

To gain insight into the spectrum of genes that are deregulated or aberrantly spliced in association with *SF3B1* mutation in the hematopoietic stem and progenitor cells (HSPC) of MDS patients, we used deep RNA-Seq to compare the transcriptome of bone marrow CD34^+^ cells from eight MDS patients with *SF3B1* mutation (*SF3B1* mutants), four MDS patients with no known splicing mutation (wild type) and five healthy controls (control) ([Supplementary Table S3](#sup1){ref-type="supplementary-material"}). Using IGV, we evaluated the expression of the *SF3B1* alleles in *SF3B1* mutant cases and observed a range of 45--52% of mutant allele frequency, indicating that both wild-type and mutant alleles were equally expressed ([Supplementary Table S3](#sup1){ref-type="supplementary-material"}, [Supplementary Figure S4](#sup1){ref-type="supplementary-material"}).

We used edgeR to perform differential gene expression analysis of *SF3B1* mutants versus wild type and control. At the whole transcript level, we observed a total of 526 genes (253 upregulated and 273 downregulated) significantly differentially expressed in *SF3B1* mutants in comparison with wild type ([Supplementary Table S5](#sup1){ref-type="supplementary-material"}). In the comparison of *SF3B1* mutants with control, we found 1823 significantly differentially expressed genes (646 upregulated and 1177 downregulated) ([Supplementary Table S6](#sup1){ref-type="supplementary-material"}). Genes linked to the pathogenesis of RARS and RCMD-RS, such as *ALAS2* and *ABCB7*, were deregulated (*ALAS2* upregulated and *ABCB7* downregulated) in both comparisons of *SF3B1* mutant with wild type and control. We also observed upregulation of the mitochondrial genes *SLC25A37* when comparing *SF3B1* mutant with control and *GLRX5* in both comparisons of *SF3B1* mutant with wild type and control.

We performed an analysis using 121 genes either known to be expressed in erythroid cells^[@bib30]^ or described as erythroid transcription factors in the literature. We found 42 differentially expressed genes (37 upregulated and 5 downregulated) when comparing *SF3B1* mutant with control. These included heme biosynthetic enzymes (for example, *ALAS2*, *ALAD*, *FECH* and *UROD*), globin genes (for example, *HBQ1*, *HBA2*, *HBB* and *HBA1*) and transcription factors (for example, *GATA1*, *GATA2* and *KLF1*). In the comparison of *SF3B1* mutant with wild type, we found a total of 32 differentially expressed genes (31 upregulated and 1 downregulated) of which 28 were overlapping with the differentially expressed genes found when comparing *SF3B1* mutant with control.

We then performed pathway analysis on the significantly differentially expressed genes using IPA. Many pathways, including heme biosynthesis, mitotic roles of polo-like kinase and TNFR2 signaling, were significantly deregulated in the comparison of *SF3B1* mutant with wild type ([Table 3](#tbl3){ref-type="table"}). When comparing *SF3B1* mutant with control, significantly deregulated pathways included apoptosis signaling, p53 signaling, cell cycle regulation and heme degradation ([Supplementary Table S7](#sup1){ref-type="supplementary-material"}). We next performed Gene Set Enrichment Analysisand many gene sets showing significant enrichment were identified in *SF3B1* mutant versus wild type and control. Upregulated gene sets included several that were related to mitochondrial function, cell cycle checkpoints and mRNA splicing. In the comparison of *SF3B1* mutant with control cases, downregulated gene sets included several that were related to cell differentiation and apoptosis ([Supplementary Table S8](#sup1){ref-type="supplementary-material"}). Many of these deregulated pathways and gene sets are relevant to the known pathophysiology of MDS and in particular of RARS and RCMD-RS.

DEXSeq was used to perform differential exon usage analysis of the RNAseq data to evaluate aberrantly spliced genes. At the exon level, we observed a total of 3506 exons (corresponding to 1924 genes) significantly differentially expressed in *SF3B1* mutant compared with control ([Table 4](#tbl4){ref-type="table"}, [Figure 3](#fig3){ref-type="fig"}, [Supplementary Table S9](#sup1){ref-type="supplementary-material"}). Differential exon usage was observed in at least one exon of genes known to be involved in MDS pathophysiology (*TP53* and *EZH1*), erythroid genes (*ALAD, UROD* and *EPB42*) and genes associated with cell cycle (*AURKB* and *CRNDE*) and RNA processing (*RBM5, RBM25, PRPF40A* and *HNRNPD*). When comparing *SF3B1* mutant with wild type cases, we found 3097 significantly differentially expressed exons (corresponding to 2022 genes) ([Table 5](#tbl5){ref-type="table"}, [Figure 4](#fig4){ref-type="fig"}, [Supplementary Table S10](#sup1){ref-type="supplementary-material"}). We found differential exon usage in at least one exon of genes involved in MDS pathophysiology (*CBL, ASXL1* and *DNMT3A*), mitochondrial function (*ALAS2, NDUFAF6*), erythroid differentiation (*NFE2L2, PPOX* and *HMBS*) and mRNA processing (*HNRNPD, U2AF2* and *PRPF8*). Interestingly, *UQCC1*, a gene involved in mitochondrial biogenesis^[@bib31]^ and showing abnormal splicing in *SF3B1* mutant cases in uveal melanoma,^[@bib32]^ showed differential exon usage and upregulation in *SF3B1* mutant cases compared with wild type and control in our study.

To identify pathways affected by differential exon usage, we performed pathway analysis on the genes showing significantly differentially expressed exons using IPA. In the comparison of *SF3B1* mutant with wild type and control, we observed many pathways to be affected, including cell cycle, heme biosynthesis, DNA damage response, mitochondrial and haematopoietic progenitor cells pathway ([Supplementary Table S11 and S12](#sup1){ref-type="supplementary-material"}). Using DAVID functional annotation tool, we observed significant enrichment of biological themes including alternative splicing, RNA binding, mitochondrion, spliceosome and cell cycle.

Recently, a role for SF3B1 in the maintenance of genomic stability has also been reported where it functions in a DNA damage-induced mRNA splicing complex with BRCA1 and BCLAF1.^[@bib33]^ Given that deregulation of the DNA damage response pathway was highlighted by the IPA pathway analysis, we performed an analysis using genes regulated by the BRCA1--BCLAF1--SF3B1 complex. Several genes regulated by this complex showed differential exon usage in *SF3B1* mutant compared with control (including *NUMA1, RB1, CHUK* and *ABL1*) and compared with wild type (*NUMA1*, *PIAS1*, *SMAD4*, *BIRC2* and *PTK2)* ([Supplementary Table S13](#sup1){ref-type="supplementary-material"}). The overrepresentation of genes regulated by the BRCA1--BCLAF1--SF3B1 complex was significant in *SF3B1* mutant compared with control (*P*\<0.001) and compared with wild type (*P*=0.0498, hypergeometric test). We also found many genes to be affected at the transcript level, including *BIRC3*, *BCL2A1, GYPB, HBB* and *HBBP1* when comparing *SF3B1* mutant with wild type and control ([Supplementary Table S13](#sup1){ref-type="supplementary-material"}).

Discussion
==========

The identification of frequent somatic mutations of *SF3B1* in MDS patients with ring sideroblasts suggests a direct correlation between the presence of mutations and this particular phenotype.^[@bib2],\ [@bib11],\ [@bib13]^ However, the mechanism by which *SF3B1* mutation leads to MDS with ring sideroblasts remains to be elucidated.

To illuminate the role of *SF3B1* mutation in MDS pathophysiology, we have determined the effects of *SF3B1* disruption on cell growth and gene expression in human hematological cells. First, we investigated the effects of *SF3B1* knockdown on cell function and gene expression in myeloid cell lines. Second, we used RNA-Seq to study the global gene expression changes and splicing abnormalities associated with the presence of *SF3B1* mutations in the HSPC of MDS patients.

We have shown that *SF3B1* knockdown in four myeloid cell lines resulted in inhibition of cell growth and disruption of the cell cycle. It has recently been reported that Sf3b1^+/−^ mice showed reduced numbers of HSC and compromised reconstitution capacity in lethally irradiated mice.^[@bib14],\ [@bib15]^ Thus, reduced expression of *SF3B1* appears to result in impaired cell growth in hematopoietic cells. Similar observations have been made following reduced expression of other splicing factor genes, including *U2AF1*.^[@bib3],\ [@bib4],\ [@bib34]^

We used two different microarray platforms to identify genes deregulated at the transcriptional and exon level by *SF3B1* knockdown in myeloid cell lines. Gene expression profiling identified many deregulated genes, with four genes consistently upregulated, including *TFDP1,* and five genes downregulated, including *CREBZF,* in all four cell lines with *SF3B1* knockdown, several of which have a role in the control of cell growth. *TFDP1* is involved in the control of transcriptional activity of G1/S cell cycle checkpoint genes,^[@bib35]^ and *CREBZF* is a potent suppressor of cell growth, the effects of which are mediated through the tumor suppressor p53.^[@bib36]^ Next, we employed exon-junction arrays to study the transcriptome in K562 and TF1 cells. We identified many differentially expressed exons and differentially regulated splicing variants in cells with *SF3B1* knockdown. For example, we observed differential exon usage of the *CDC7* and *SRSF11* genes, involved in cell cycle regulation and splicing, respectively, and of the *TP53* gene. Several pathways including cell cycle, RNA processing, mitochondrion and apoptosis/p53 pathway were consistently deregulated in the cell lines with *SF3B1* knockdown.

In summary, our data on myeloid cell lines suggest that the phenotype observed in cells with *SF3B1* knockdown is mediated by aberrant splicing and expression of target genes involved in key biological processes.

RNA-Seq is the method of choice for a comprehensive analysis of global gene expression and splicing. In all relevant studies published to date, RNA-Seq has been performed on unfractionated bone marrow mononuclear cells from a small number of MDS patients with *SF3B1* mutations (*n*⩽3 per study), revealing interesting data.^[@bib11],\ [@bib37],\ [@bib38]^ MDS arise in the HSC, and it is thus of critical importance that the effects of *SF3B1* mutation on the transcriptome are studied in the cell of origin. In this study, we performed RNA-Seq on purified bone marrow CD34^+^ cells from 12 MDS patients, eight with ring sideroblasts and *SF3B1* mutation and four without mutation in other splicing factor genes, and from five healthy controls.

We identified many significantly differentially expressed genes at the transcript level and the exon level when comparing *SF3B1* mutant with wild type and control. CD34^+^ cells from RCMD-RS and RARS patients display a particular expression profile of mitochondria-related genes;^[@bib17],\ [@bib20]^ we observed upregulation of *ALAS2* (heme biosynthesis enzyme) and downregulation of *ABCB7* (involved in the transport of iron from the mitochondria to the cytoplasm) in *SF3B1* mutants compared with wild type and control, in agreement with our previous reports.^[@bib17],\ [@bib20]^ *SLC25A37*, encoding a mitochondrial iron importer, and *GLRX5*, encoding another mitochondrial protein, were both significantly upregulated in CD34^+^ cells of *SF3B1* mutants compared with wild type and control. A recent study showed *SLC25A37* mRNA upregulation in *SF3B1* mutant bone marrow mononuclear cells of three MDS patients with RARS/-T.^[@bib38]^ Evidence is thus mounting to suggest that upregulation of the iron importer *SLC25A37* and downregulation of iron exporter *ABCB7* may be linked to the increased mitochondrial iron accumulation observed in MDS patients with ring sideroblasts.^[@bib39]^ Deregulation of these genes could also be consistent with an impaired ability of mitochondrial pathways to use iron that may result in an attempt to increase iron availability.

Importantly, we observed many genes associated with porphyrin and heme biosynthesis showing differential exon usage in *SF3B1* mutant cases, indicating altered splicing. These include *ALAD* and *UROD* when comparing *SF3B1* mutant with control and *ALAS2* and *PPOX* when comparing with wild type. We suggest that the aberrant expression and exon usage of mitochondrial and heme-related genes in the CD34^+^ cells of MDS patients with *SF3B1* mutation has a role in ring sideroblast formation and abnormal iron homeostasis observed in this patient group. Intriguingly, the most common congenital sideroblastic anemia (X-linked sideroblastic anemia) results from an *ALAS2* mutation.^[@bib40]^

The relative expression levels of the transcription factors *GATA1* and *GATA2* differed from normal in the CD34^+^ cells of MDS patients with *SF3B1* mutation. The dynamic and strictly regulated change of expression from *GATA2* to *GATA1* during erythropoiesis has a crucial role,^[@bib41]^ and any alteration of this pattern may be predicted to lead to aberrant erythropoiesis. We suggest that the aberrant expression and splicing of erythroid-related genes observed in the CD34^+^ cells of MDS patients with *SF3B1* mutation may have a role in the ineffective erythropoiesis found in these patients.

In a previous study, RNA-Seq was used to compare the transcriptome of bone marrow mononuclear cells of two MDS patients with *SF3B1* mutation to that of one healthy control.^[@bib11]^ One hundred and thirty genes showed significant differential expression, 28 of which overlap with the genes differentially expressed between *SF3B1* mutant and control in our study of CD34^+^ cells. These genes include *MAP3K8* and *CLEC5A*, which have been previously shown to be downregulated in MDS.^[@bib19],\ [@bib42]^ Furthermore, 350 genes showed differential exon usage, and 52 of these were in common with the genes showing differential exon usage in our study of CD34^+^ cells. The overlapping genes include *EZH1*, *ASXL1, CBL1* and *SMAD4*.

The mutant forms of *ASXL1*, *CBL* and *TP53* are known to have an important role in the molecular pathogenesis of MDS, and intriguingly all these genes were found to be alternatively spliced in the HSPC of MDS patients harboring *SF3B1* mutations.

A recent study identified a DNA damage-induced BRCA1 protein complex containing BCLAF1 and SF3B1 (BRCA1--BCLAF1--SF3B1 complex).^[@bib33]^ In response to DNA damage, the complex regulates pre-mRNA splicing of genes involved in DNA damage signaling and repair and hence affects their transcription and pre-mRNA maturation.^[@bib33]^ Importantly, we found many of the genes regulated by this complex to be differentially expressed and to show differential exon usage in our study. Genes showing differential transcript level changes included *BIRC3* and *BCL2A1*, whereas *NUMA1* showed differential exon usage when comparing *SF3B1* mutant with wild type and control. When comparing *SF3B1* mutant with wild type, we also found differential exon usage of the *PIAS1* gene, a DNA damage response regulator.^[@bib43],\ [@bib44]^ It has been demonstrated that abrogation of members of this complex including BRCA1 and BCLAF1 results in genomic instability,^[@bib33]^ a common feature of malignant cells. In MDS patients with mutant *SF3B1*, the function of this complex may be impaired, with possible downstream effects on the efficiency of DNA damage repair.

Many genes involved in RNA splicing and processing were found to show differential transcript levels, as well as differential exon usage in our study, including *HNRNPD, U2AF2, PRPF8* and *RBM25*. A recent study showed RNA processing genes to be misspliced in the bone marrow mononuclear cells of MDS/AML patients with *U2AF1* mutation.^[@bib45]^ Intriguingly, there is limited overlap between the genes misspliced as a result of *U2AF1* mutation and the RNA processing/splicing genes deregulated/aberrantly spliced in our *SF3B1* mutant cases in both comparisons of *SF3B1* mutant with wild type and control, suggesting that this process may be affected by different splicing mutations even if their target genes are distinct.

A recent study showed that defects in the splicing factor gene *PRPF8* result in missplicing in myeloid malignancies and are associated with the presence of ring sideroblasts in advanced MDS and AML.^[@bib46]^ Interestingly, we observed differential exon usage of *PRPF8* in *SF3B1* mutant cases compared with control in our study, indicating a link between *SF3B1* and *PRPF8* and the ring sideroblast phenotype. Our finding of differential exon usage of multiple RNA processing/splicing genes in the HSPC of cases with *SF3B1* mutation points towards an exacerbation of aberrant splicing, with a wider number of downstream target genes affected. Emerging evidence from our study on *SF3B1* and the study on *U2AF1*^[@bib45]^ thus supports the hypothesis that in MDS patients harboring splicing factor mutations, there is widespread disruption of the splicing machinery as a consequence of downstream effects of the mutant protein. Loss-of-function mutations in zebrafish *Prpf8* have been shown to result in missplicing of *TP53*.^[@bib47]^ We found *TP53* to be aberrantly spliced in MDS patients with *SF3B1* mutation compared with wild type and control.

Splicing factor mutations, including *SF3B1*, are considered to be founder mutations and must confer a selective growth advantage to the HSC, but how this occurs remains a mystery. We have identified differential splicing in several genes known to have a role in MDS pathogenesis, including *TP53* and *ASXL1*, as well as genes involved in DNA damage repair, in the HSPC of MDS patients harboring *SF3B1* mutations. We suggest that the aberrant splicing of such genes may confer oncogenic properties that help drive the malignant process. In this study, we have determined the target genes of *SF3B1* mutations in the HSPC of MDS patients with ring sideroblasts, shedding light on the mechanisms underlying this phenotype.
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![Effects of *SF3B1* knockdown in myeloid cell lines. Each cell line transfected with siRNA targeting *SF3B1* was compared with the corresponding cell line transfected with the scramble control. (**a**) *SF3B1* mRNA expression measured 3 days after knockdown. (**b**) Growth curves of cells with *SF3B1* knockdown, compared with cells transfected with the scramble control, as assessed by trypan blue exclusion. (**c**) Cell cycle analysis of cell lines following *SF3B1* knockdown. (**d**) Erythroid differentiation in myeloid cell lines with *SF3B1* knockdown treated with 50 μ[m]{.smallcaps} hemin, as measured by *HBG1* and *KLF1* expressions relative to the scramble control. (**e**) Percentage of CD36+CD71+ and CD71+CD235a+ populations in K562 cells with *SF3B1* knockdown compared with the scramble control. Results in subpanels **a**--**d** were obtained from scramble *n*=2 and *SF3B1* siRNA as follows: **a**, *n*=3; **b**, *n*=3; **c**, *n*=3 for SKM1 and TF1, *n*=6 for HEL and *n*=9 for K562; **d**, *n*=3 for TF1 and HEL, *n*=6 for K562. Results in subpanel **e** were obtained from scramble *n*=4 and *SF3B1* siRNA *n*=4. \**P*\<0.05.](leu2014331f1){#fig1}

![Effects of *SF3B1* knockdown on gene expression and splicing. (**a**) *ABCB7* and *FTMT* expression levels in TF1, K562, HEL and SKM1 cells with *SF3B1* knockdown, as measured by qRT-PCR 48 h post transfection. Each cell line transfected with siRNA targeting *SF3B1* was compared with the corresponding cell line transfected with the scramble control. (**b**) Reverse transcription-PCR of *TP53* exons 5--7 showing aberrant splicing in K562 cells with *SF3B1* knockdown (siRNA) compared with scramble (SCR). (**c**, **d**). qRT-PCR analysis using primers that monitor general gene expression (GE) in a constitutive exon (Ex4 of *CCNA2* and Ex3 of *STK6*) or primers specific for splice junctions corresponding to exon inclusion or skipping in the cyclin A2 (*CCNA2*) and Aurora Kinase A (*STK6*) genes in K562 cells. Cells with *SF3B1* knockdown (siRNA) show alternative splicing events. Results in subpanel **a** were obtained from scramble *n*=3 and *SF3B1* siRNA *n*=4. Results in subpanel **c**--**d** were obtained from scramble *n*=2 and *SF3B1* siRNA *n*=3. \**P*\<0.05.](leu2014331f2){#fig2}

![Examples of genes showing significant differential exon usage between MDS patients with *SF3B1* mutation in comparison with control, obtained from RNA-Seq data analysis using DEXSeq. The graphs show some of the top ranking genes with significant differential exon usage. The exons highlighted in purple represent the significant differential exon usage.](leu2014331f3){#fig3}

![Examples of genes showing significant differential exon usage in MDS patients with *SF3B1* mutation in comparison with wild type, obtained from RNA-Seq data analysis using DEXSeq. The graphs show some of the top ranking genes with significant differential exon usage. The exons highlighted in purple represent the significant differential exon usage.](leu2014331f4){#fig4}

###### List of significant deregulated pathways in cell lines obtained using IPA

  *TF1*                                                                          *SKM1*                                          *K562*                                                  *HEL*
  ------------------------------------------------------------- ---------------------------------------- ------------------------------------------------------- -----------------------------------------------------
  Selenoamino acid metabolism                                       Estrogen-mediated S-phase entry                          AMPK signaling                                 Estrogen-mediated S-phase entry
  Mitochondrial dysfunction                                            Pentose phosphate pathway                             HMGB1 signaling                               Cyclins and cell cycle regulation
  AMPK signaling                                                 Cell cycle: G1/S checkpoint regulation                      mTOR signaling                                 PI3K signaling in B lymphocytes
  Regulation of eIF4 and p70S6K signaling                           Small-cell lung cancer signaling              Polyamine regulation in colon cancer                              mTOR signaling
  mTOR signaling                                                          Lysine biosynthesis                 Cell cycle regulation by BTG family proteins               Breast cancer regulation by stathmin1
  Role of NANOG in mammalian embryonic stem cell pluripotency         Actin cytoskeleton signaling                            ILK signaling                                        Purine metabolism
  Cyclins and cell cycle regulation                                Chronic myeloid leukemia signaling               Cyclins and cell cycle regulation                              Glioma signaling
  Polyamine regulation in colon cancer                                      Glioma signaling                               Ceramide signaling                          Aldosterone signaling in epithelial cells
  Assembly of RNA polymerase II complex                          Assembly of RNA polymerase III complex                      ErbB signaling                                  fMLP signaling in neutrophils
                                                                    Signaling by Rho family GTPases                          TNFR1 signaling                            Cell cycle: G1/S checkpoint regulation
                                                                                                                    Glucocorticoid receptor signaling                    Non-small cell lung cancer signaling
                                                                                                                Glycine, serine and threonine metabolism                       Growth hormone signaling
                                                                                                          Role of CHK proteins in cell cycle checkpoint control            Small-cell lung cancer signaling
                                                                                                                           VDR/RXR activation                               Protein ubiquitination pathway
                                                                                                                           Lysine degradation                     Nitric oxide signaling in the cardiovascular system
                                                                                                                        Tight junction signaling                                    AMPK signaling
                                                                                                                         Ubiquinone biosynthesis                           Glioblastoma multiforme signaling
                                                                                                                    Mitotic roles of polo-like kinase                                       
                                                                                                                         Wnt/β-catenin signaling                                            
                                                                                                                           PI3K/AKT signaling                                               
                                                                                                                     Renal cell carcinoma signaling                                         
                                                                                                                 Regulation of eIF4 and p70S6K signaling                                    
                                                                                                                             TNFR2 signaling                                                
                                                                                                                     Fructose and mannose metabolism                                        
                                                                                                                          Telomerase signaling                                              

Gene expression profiling was performed in all four cell lines with *SF3B1* knockdown, and genes showing \>2-fold change were used for the analysis.

###### Pathway analysis using human genome exon-junction array data at two different levels: differential exon usage and different splicing variant

  *Pathways affected by diferential exon usage*            *Pathways affected by differential splice variant usage*                                            
  ------------------------------------------------------- ---------------------------------------------------------- ----------------------------------------- ----------
  *KEGG pathway*                                                                                                                                               
   Ubiquitin-mediated proteolysis                                                  1.82E−05                                       RNA degradation               7.85E−05
   Cell cycle                                                                      1.02E−04                                       Oocyte meiosis                4.23E−03
   Spliceosome                                                                     3.22E−04                                         Cell cycle                  8.45E−03
   Oocyte meiosis                                                                  3.88E−04                           Progesterone-mediated oocyte maturation   2.17E−02
   Phosphatidylinositol signaling system                                           8.92E−04                                 Aminoacyl-tRNA biosynthesis         4.04E−02
   Inositol phosphate metabolism                                                   1.68E−03                                                                         
   RNA degradation                                                                 2.30E−02                                                                         
   Ribosome                                                                        2.58E−02                                                                         
   One carbon pool by folate                                                       2.65E−02                                                                         
   Aminoacyl-tRNA biosynthesis                                                     2.91E−02                                                                         
   Selenoamino acid metabolism                                                     3.93E−02                                                                         
   Insulin signaling pathway                                                       4.03E−02                                                                         
                                                                                                                                                                    
  *REACTOME pathway*                                                                                                                                           
   Cell cycle, mitotic                                                             1.19E−09                                     Cell cycle, mitotic             4.43E−05
   Gene expression                                                                 1.47E−04                                       Gene expression               1.29E−02
   DNA repair                                                                      1.75E−03                                   Cell cycle checkpoints            2.20E−02
   APC-Cdc20-mediated degradation of Nek2A                                         9.97E−03                                                                         
   Cell cycle checkpoints                                                          1.13E−02                                                                         
   Transcription                                                                   1.22E−02                                                                         
   Signaling by Wnt                                                                2.91E−02                                                                         
   Signaling by NGF                                                                3.63E−02                                                                         
   Cdc20:Phospho-APC/C-mediated degradation of cyclin A                            4.70E−02                                                                         

###### Pathway analysis (IPA) of the significant differentially expressed genes between *SF3B1* mutant and wild type obtained using edgeR

  *Ingenuity canonical pathways*                                                                          P*-value*     *Ratio*                                              *Molecules*
  ------------------------------------------------------------------------------------------------------- ------------- ---------- ------------------------------------------------------------------------------------------------
  Lymphotoxin β receptor signaling                                                                        0.00074131    9.68E−02                             NFKBID, BCL2L1, CASP3, RELB, CXCL1 and TRAF1
  Agranulocyte adhesion and diapedesis                                                                    0.001071519   5.73E−02    CXCL3, PODXL2, CCL4,CLDN19, CXCL14, CXCL1, CCL3L1/CCL3L3, MMP2, CXCL2, MYH7B and CCL4L1/CCL4L2
  Heme biosynthesis II                                                                                    0.001096478   1.67E−01                                      FECH, ALAS2, CPOX and HMBS
  Hepatic fibrosis/hepatic stellate cell activation                                                       0.00162181    5.81E−02                       CXCL3, LEPR, IL6R, MMP2, LBP, IL6, MYH7B, AGTR1 and PGF
  Communication between innate and adaptive immune cells                                                  0.001995262   6.25E−02                        CCL4, TLR7, CCL3L1/CCL3L3, CD83, IGHG1, IGHA1 and IL6
  Colorectal cancer metastasis signaling                                                                  0.003467369   4.48E−02            BCL2L1, ADCY9, CDH1, JUN, CASP3, PTGER3, DIRAS3, IL6R, TLR7, MMP2, IL6 and PGF
  IL-17A signaling in fibroblasts                                                                         0.004570882   1E−01                                        NFKBID, JUN, IL6 and NFKBIZ
  Toll-like receptor signaling                                                                            0.004570882   7.81E−02                                  JUN, TLR7, TNFAIP3, LBP and TRAF1
  Differential regulation of cytokine production in macrophages and T-helper cells by IL-17A and IL-17F   0.004786301   1.67E−01                                         CCL4, CXCL1 and IL6
  Granulocyte adhesion and diapedesis                                                                     0.007762471   4.95E−02           CXCL3, CCL4, CLDN19, CXCL14, CXCL1, CCL3L1/CCL3L3, MMP2, CXCL2 and CCL4L1/CCL4L2
  Airway pathology in chronic obstructive pulmonary disease                                               0.009772372   1.82E−01                                            CXCL3 and MMP2
  TNFR2 signaling                                                                                         0.016595869   8.82E−02                                        JUN, TNFAIP3 and TRAF1
  Heme bosynthesis from uroporphyrinogen-III I                                                            0.018620871   1.82E−01                                            FECH and CPOX
  Aryl hydrocarbon receptor signaling                                                                     0.024547089   4.09E−02                            TGM2, CCNE1, GSTM2, ALDH1A1, JUN, NQO2 and IL6
  NRF2-mediated oxidative stress response                                                                 0.025118864   4.1E−02                          GSR, JUN, GSTM2, NQO2, DNAJC6, JUND, FOSL1 and ABCC4
  Role of IL-17A in psoriasis                                                                             0.025703958   1.43E−01                                           CXCL3 and CXCL1
  Gα12/13 signaling                                                                                       0.028840315   4.72E−02                                BTK, CDH7, CDH1, JUN, MEF2D and CDH11
  Tetrapyrrole biosynthesis II                                                                            0.029512092   1.43E−01                                            ALAS2 and HMBS
  CDK5 signaling                                                                                          0.033884416   5.15E−02                                 FOSB, PPP1CC, ADCY9, PPM1J and EGR1
  CD40 signaling                                                                                          0.033884416   5.63E−02                                   JUN, TNFAIP3, MAPKAPK2 and TRAF1
  Mitotic roles of polo-like kinase                                                                       0.041686938   5.41E−02                                    PLK3, PPM1J, ANAPC13 and CCNB1
  Adenine and adenosine salvage III                                                                       0.042657952   1.18E−01                                            PNP and ADAT3
  Tryptophan degradation to 2-amino-3-carboxymuconate semialdehyde                                        0.046773514   1.11E−01                                            HAAO and KYNU
  T-helper cell differentiation                                                                           0.047863009   5.56E−02                                      STAT4, IL6R, IL6 and RORC

###### Top ranking genes showing differential exon usage between *SF3B1* mutant and control, obtained from RNA sequencing data analysis using DEXSeq

  *Gene ID*          *Exon ID*    *Gene name*    *Chromosome*   *Strand*  P*-value*   P~*adj*~   *FC*
  ----------------- ----------- --------------- -------------- ---------- ----------- ---------- -------------
  ENSG00000125354      E011          SEPT6            X            −1     1.67E−78    5.19E−73   0.822522658
  ENSG00000111843      E006         TMEM14C           6            1      2.80E−51    4.36E−46   0.803897136
  ENSG00000131669      E006          NINJ1            9            −1     1.09E−33    1.13E−28   0.835812796
  ENSG00000088986      E014         DYNLL1            12           1      1.21E−28    9.43E−24   0.913566493
  ENSG00000223865      E018        HLA-DPB1           6            1      3.05E−27    1.90E−22   1.357267219
  ENSG00000101019      E025          UQCC1            20           −1     1.71E−26    8.88E−22   0.889537433
  ENSG00000132199      E025         ENOSF1            18           −1     2.57E−24    1.14E−19   0.905515696
  ENSG00000125991      E049         ERGIC3            20           1      4.11E−23    1.42E−18   0.870728412
  ENSG00000101019      E024          UQCC1            20           −1     2.01E−22    6.25E−18   0.878172451
  ENSG00000118495      E010         PLAGL1            6            −1     2.78E−22    7.85E−18   1.753766932
  ENSG00000266086      E005      RP11-159D12.5        17           −1     1.43E−18    3.43E−14   1.051487592
  ENSG00000119777      E023         TMEM214           2            1      1.35E−18    3.43E−14   0.724952987
  ENSG00000130066      E011          SAT1             X            1      2.63E−17    5.83E−13   1.224469811
  ENSG00000101019      E029          UQCC1            20           −1     3.49E−17    7.24E−13   0.987866168
  ENSG00000141425      E015         RPRD1A            18           −1     2.14E−16    3.91E−12   1.151614234
  ENSG00000268400      E058      CTD-3214H19.4        19           1      2.08E−16    3.91E−12   0.720165623
  ENSG00000127586      E055         CHTF18            16           1      2.45E−16    4.24E−12   0.83461565
  ENSG00000130066      E015          SAT1             X            1      4.80E−16    7.86E−12   1.112053709
  ENSG00000160789      E072          LMNA             1            1      1.00E−15    1.56E−11   0.74131183
  ENSG00000130066      E010          SAT1             X            1      1.22E−15    1.81E−11   1.175909464
  ENSG00000119777      E024         TMEM214           2            1      6.13E−15    8.66E−11   0.769414939
  ENSG00000266086      E004      RP11-159D12.5        17           −1     1.51E−14    2.04E−10   1.073999383
  ENSG00000168675      E009         LDLRAD4           18           1      4.10E−14    5.10E−10   0.882283199
  ENSG00000160789      E071          LMNA             1            1      6.34E−14    7.58E−10   0.907377148
  ENSG00000214021      E019          TTLL3            3            1      1.13E−13    1.30E−09   1.027729333
  ENSG00000196576      E041         PLXNB2            22           −1     1.59E−13    1.77E−09   0.53703246
  ENSG00000166508      E021          MCM7             7            −1     2.21E−13    2.37E−09   1.034956343
  ENSG00000114770      E040          ABCC5            3            −1     2.75E−13    2.79E−09   1.290748901
  ENSG00000196365      E028          LONP1            19           −1     2.78E−13    2.79E−09   0.876937237
  ENSG00000130066      E002          SAT1             X            1      3.59E−13    3.49E−09   0.967812734
  ENSG00000102119      E017           EMD             X            1      3.76E−13    3.55E−09   1.050545479
  ENSG00000130066      E014          SAT1             X            1      5.55E−13    5.08E−09   1.168469304
  ENSG00000266086      E006      RP11-159D12.5        17           −1     5.72E−13    5.08E−09   1.073091463
  ENSG00000055609      E005          KMT2C            7            −1     6.09E−13    5.26E−09   1.089688525
  ENSG00000228315      E065         GUSBP11           22           −1     6.70E−13    5.63E−09   1.125912723
  ENSG00000156860      E023          FBRS             16           1      7.27E−13    5.95E−09   1.10075677
  ENSG00000268400      E071      CTD-3214H19.4        19           1      8.37E−13    6.67E−09   1.139015436
  ENSG00000214021      E065          TTLL3            3            1      1.15E−12    8.34E−09   1.269221488
  ENSG00000122566      E004        HNRNPA2B1          7            −1     1.10E−12    8.34E−09   1.160615984
  ENSG00000101557      E035          USP14            18           1      1.13E−12    8.34E−09   1.043528763

Genes are ranked by adjusted *P*-value (*P*~adj~).

###### Top ranking genes showing differential exon usage between *SF3B1* mutant and wild type, obtained from RNA sequencing data analysis using DEXSeq

  *Gene ID*          *Exon ID*    *Gene name*    *Chromosome*   *Strand*  P*-value*   P~*adj*~   *FC*
  ----------------- ----------- --------------- -------------- ---------- ----------- ---------- -------------
  ENSG00000125354      E011          SEPT6            X            −1     9.38E−92    3.53E−86   0.827252395
  ENSG00000132199      E025         ENOSF1            18           −1     5.10E−33    9.59E−28   0.911519852
  ENSG00000189283      E004          FHIT             3            −1     1.73E−28    2.18E−23   3.663047029
  ENSG00000101019      E025          UQCC1            20           −1     9.24E−28    8.69E−23   0.72317914
  ENSG00000111843      E006         TMEM14C           6            1      9.84E−26    7.40E−21   0.91596329
  ENSG00000125991      E049         ERGIC3            20           1      9.81E−23    6.15E−18   0.791616483
  ENSG00000071082      E025          RPL31            2            1      3.50E−21    1.88E−16   0.717351893
  ENSG00000101019      E029          UQCC1            20           −1     2.62E−20    1.23E−15   0.701671242
  ENSG00000211644      E016        IGLV1-51           22           1      3.99E−20    1.67E−15   0.441359946
  ENSG00000088986      E014         DYNLL1            12           1      5.65E−20    2.12E−15   0.845893878
  ENSG00000028310      E077          BRD9             5            −1     3.97E−18    1.36E−13   0.767361674
  ENSG00000127586      E055         CHTF18            16           1      2.12E−17    6.64E−13   0.878313474
  ENSG00000101019      E007          UQCC1            20           −1     3.20E−17    9.25E−13   1.47227241
  ENSG00000160710      E024          ADAR             1            −1     1.30E−16    3.51E−12   1.320985378
  ENSG00000101019      E024          UQCC1            20           −1     2.02E−16    5.06E−12   0.71746253
  ENSG00000118495      E010         PLAGL1            6            −1     4.10E−16    9.65E−12   2.538692764
  ENSG00000255863      E017       AC073610.5          12           −1     1.20E−15    2.65E−11   0.882954589
  ENSG00000211644      E017        IGLV1-51           22           1      1.38E−15    2.88E−11   0.485819764
  ENSG00000075218      E014          GTSE1            22           1      2.48E−15    4.91E−11   1.468605485
  ENSG00000137133      E004          HINT2            9            −1     2.09E−14    3.93E−10   0.839329231
  ENSG00000205593      E031         DENND6B           22           −1     5.28E−14    9.46E−10   4.609575952
  ENSG00000101019      E013          UQCC1            20           −1     1.05E−13    1.74E−09   2.895712194
  ENSG00000101019      E026          UQCC1            20           −1     1.11E−13    1.74E−09   0.732192837
  ENSG00000101019      E028          UQCC1            20           −1     1.10E−13    1.74E−09   0.698206407
  ENSG00000103426      E028       CORO7-PAM16         16           −1     1.21E−13    1.83E−09   0.838759667
  ENSG00000205593      E030         DENND6B           22           −1     3.43E−13    4.97E−09   4.61396886
  ENSG00000101019      E010          UQCC1            20           −1     4.54E−13    6.33E−09   1.74387423
  ENSG00000111640      E017          GAPDH            12           1      8.37E−13    1.12E−08   1.387332969
  ENSG00000100387      E034          RBX1             22           1      1.24E−12    1.61E−08   1.875629945
  ENSG00000271270      E006        TMCC1-AS1          3            1      2.12E−12    2.66E−08   2.979442225
  ENSG00000028310      E078          BRD9             5            −1     3.00E−12    3.64E−08   0.795339192
  ENSG00000101019      E027          UQCC1            20           −1     3.26E−12    3.84E−08   0.703747197
  ENSG00000255103      E077        KIAA0754           1            1      3.38E−12    3.85E−08   1.663519412
  ENSG00000268400      E035      CTD-3214H19.4        19           1      3.57E−12    3.95E−08   1.463054031
  ENSG00000205593      E032         DENND6B           22           −1     4.28E−12    4.60E−08   4.764064117
  ENSG00000136044      E042          APPL2            12           −1     5.63E−12    5.88E−08   0.720698938
  ENSG00000101019      E005          UQCC1            20           −1     1.00E−11    9.92E−08   1.53637968
  ENSG00000167323      E043          STIM1            11           1      9.97E−12    9.92E−08   0.766910234
  ENSG00000101019      E016          UQCC1            20           −1     1.35E−11    1.28E−07   2.2692562
  ENSG00000161013      E025         MGAT4B            5            −1     1.36E−11    1.28E−07   1.097105348

Genes are ranked by adjusted *P*-value (*P*~adj~).

[^1]: These authors contributed equally to this work.
